Correlation between the incidence of type 2 diabetes mellitus to Chinese visceral adiposity index in a community population of Chongqing City / 解放军医学杂志

Objective To investigate the correlation between the Chinese visceral adiposity index (CVAI) and the morbidity risk of type 2 diabetes mellitus (T2DM). Methods A total of 6426 subjects (3568 males, 2858 females) from a community of Chongqing City who participated in a medical examination in 2013 were recruited. After exclusion of faulty data or missing information, the final samples for analysis included 5039 subjects (2834 males, 2205 females). Subjects were firstly divided into male group and female group, and then, according to CVAI index quartiles, the both groups were respectively divided into 1st (Q1), 2nd (Q2), 3rd (Q3) and 4th (Q4) quantile group. Anthropometric data (including blood glucose, lipid levels, uric acid) were compared among each group. The risk of T2DM in subjects with different CVAI index was analyzed with logistic regression analysis. Results After adjusting possible confounding factors affecting diabetes, such as age, systolic pressure, diastolic pressure, levels of total cholesterol, triglyceride, low-density lipoprotein and uric acid, compared with the risks of T2DM in 1st (Q1) CVAI quartiles, that in 2nd (Q2), 3rd (Q3) and 4th (Q4) CVAI quartiles for males were 1.146 (OR=1.146, 95%CI: 0.764-1.718), 2.033 (OR=2.033, 95%CI: 1.378-3.000) and 3.247 (OR=3.247, 95%CI: 2.175-4.849), and that in 2nd (Q2), 3rd (Q3) and 4th (Q4) CVAI quartiles for females were 1.583 (OR=1.583, 95%CI: 0.634-3.954), 3.108 (OR=3.108, 95%CI: 1.222-7.905) and 3.814 (OR=3.814, 95%CI: 1.350-10.733). Conclusion Higher CVAI is the independent risk factor for the T2DM in Chinese adults.

Effect of safflor yellow B on vascular endothelial cells injury induced by angiotensin-II / 药学学报

This study is to investigate protective effect of safflor yellow B (SYB) against vascular endothelial cells (VECs) injury induced by angiotensin-II (Ang-II). VECs were cultured and divided into six groups: control group, Ang-II group, Ang-II + SYB (1 micromolL(-1)) group, Ang-II + SYB (10 micromolL(-1)) group, Ang-II + SYB (100 micromolL(-1)) group and Ang- II + verapamil (10 micromolL(-1)) group. Except control group, all of VECs in other groups were treated with Ang- II at the final concentration of 0.1 micromolL(-1). Mitochondria membrane potential (MMP) and free calcium concentration ([Ca2+]i) were measured by laser scanning confocal microscopy, and mitochondria complex IV activity was detected by BCA method. The levels of reactive oxygen species (ROS) in VECs were analyzed by fluorescence detector and apoptosis of VECs was observed by flow cytometer. Caspase 3 was determined by Western blotting method. Comparing with control group, Ang-II was able to increase [Ca2+]i and ROS level, decrease MMP level, inhibit complex IV activity and enhance caspase 3 activity in VECs, as a result, enhance apoptosis of VECs. But SYB could significantly reduce the result induced by Ang- II relying on different dosages (P < 0.05 or P < 0.01). SYB was able to eliminate the effect of Ang-II on VECs via regulating [Ca2+]i, mitochondrial structure and function and inhibiting apoptosis.

Breast magnetic resonance imaging in patients with occult breast carcinoma: evaluation on feasibility and correlation with histopathological findings / 中华医学杂志(英文版)

<p><b>BACKGROUND</b>As an uncommon presentation, occult primary breast cancer remains a diagnostic and therapeutic challenge in clinical practice. This study aimed to retrospectively assess the feasibility of breast magnetic resonance imaging (MRI) in patients with malignant axillary lymphadenopathy and unknown primary malignancy, and correlation with histopathological characteristics.</p><p><b>METHODS</b>A total of 35 women with occult breast carcinoma were evaluated with dynamic contrast-enhanced breast MRI. Whole seriate section was used in all cases. MRI performance was assessed and correlated with histopathological findings.</p><p><b>RESULTS</b>Twenty-one of 35 patients were found to have primary breast carcinoma histologically. Twenty of the 21 patients had abnormal MR findings and 1 patient had a normal MRI study. Of the remaining 14 patients, 10 were negative on both MRI and surgery. Four had suspicious enhancement on MRI and no corresponding tumor was found. Lesions with mass enhancement were found in 55% (11/20) and ductual and segmental enhancement in 45%. The average diameter of the primary tumors was 15 mm. Invasive ductal carcinomas were found in 81% (17/21). One of 17 invasive ductual carcinomas was too small to be graded. Fourteen of the remaining 16 were classified as grade II and 2 as grade I. Thirty-two of the 35 patients had received estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 examinations and the 12 of 32 were triple-negative breast carcinoma.</p><p><b>CONCLUSIONS</b>Mass lesions with small size and lesions with ductal or segment enhancement are common MRI features in patients with occult breast cancer. The dominant types of primary tumors are invasive ductal carcinoma with moderate histopathological grade. The rate of triple-negative breast carcinoma may be higher in occult breast cancer.</p>

Chemotherapy and radiotherapy for non-Hodgkin's lymphomas of the nasal cavity / 中华肿瘤杂志

<p><b>OBJECTIVE</b>To investigate the effects of different treatments on the prognosis of patients with non-Hodgkin's lymphomas of the nasal cavity.</p><p><b>METHODS</b>A retrospective study of 59 patients who suffered from stage I(E) primary non-Hodgkin's lymphomas of the nasal cavity was presented. They were treated by radiotherapy and chemotherapy of CHOP regimen, in which 33 patients received chemotherapy plus radiotherapy, 8 patients received radiotherapy plus chemotherapy, 10 patients received chemotherapy alone, and 8 patients received radiotherapy alone. Survival analysis was performed by Kaplan-Meier method, the difference between groups was evaluated by log-rank test, and the comparison of rates was carried out by chi(2) test.</p><p><b>RESULTS</b>The overall 1-, 3- and 5-year survival rates were 71.2%, 42.0% and 38.5%, respectively. There was no significant difference among the patients received different treatments (chi(2) = 2.98, P = 0.3943), but the patients received radiotherapy plus chemotherapy seemed to have a better survival curve than other patients. The 1-, 3- and 5-year survival rates were 84.2%, 67.7% and 62.0% for lesion limited in nasal cavity but 50.0%, 14.3% and 14.3% for lesion extended and involved the adjacent structures (chi(2) = 10.46, P = 0.0012). As the initial therapy, 24 patients who received chemotherapy of more than 3 cycles, and 16 patients who received radiotherapy of more than 40 Gy, and the complete response (CR) rates were 25.0% and 75.0% (chi(2) = 9.697, P = 0.002). Among 43 patients received chemotherapy, the CR rates for those who received 2, 3 - 4 and 5 - 6 cycles were 10.5%, 25.0% and 25.0%, respectively (chi(2) = 1.467, P = 0.48). Patients who received chemotherapy plus radiotherapy have higher rates of both complication and treatment-related mortality, but the difference was not statistically significant (P = 0.202 and 0.693).</p><p><b>CONCLUSION</b>For stage I non-Hodgkin's lymphomas of the nasal cavity, radiotherapy should be the first treatment to get early local control. Chemotherapy may be followed at the discretion of the pathological grade and clinical staging, or IPI.</p>